Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1

Journal of Biological Chemistry

Volumn 290, Issue 36, 2015, Pages 21876-21889

  Amazit, Larbi ^a,b,c   Billan, Florian Le ^a,b   Kolkhof, Peter ^d   Lamribet, Khadija ^a,b   Viengchareun, Say ^a,b   Fay, Michel R ^e,f   Khan, Junaid A ^g   Hillisch, Alexander ^d   Lombès, Marc ^a,b   Rafestin Oblin, Marie Edith ^e,f   Fagart, Jérôme ^a,b,e,f  

^a Bicêtre Paris Saclay Hospital   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Univ Paris Sud   (France)

^d BAYER PHARMA AG   (Germany)

^e CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF AGRICULTURE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY;

CRITICAL STEPS; MINERALOCORTICOID RECEPTORS; NUCLEAR IMPORT; STEROID RECEPTOR COACTIVATOR-1; TARGET GENES; TRANSCRIPTIONAL CO-ACTIVATORS;

BIOLOGY;

FINERENONE; MINERALOCORTICOID RECEPTOR; RNA POLYMERASE II; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; STEROID RECEPTOR COACTIVATOR 1; ALDOSTERONE; EPITHELIAL SODIUM CHANNEL; NAPHTHYRIDINE DERIVATIVE; PROTEIN BINDING; SCNN1A PROTEIN, HUMAN;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOWN REGULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SGK1 GENE; SIGNAL TRANSDUCTION; ACTIVE TRANSPORT; CELL LINE; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; DOSE RESPONSE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; HEK293 CELL LINE; KINETICS; METABOLISM; MUTATION; PROMOTER REGION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ACTIVE TRANSPORT, CELL NUCLEUS; ALDOSTERONE; BLOTTING, WESTERN; CELL LINE; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EPITHELIAL SODIUM CHANNELS; HEK293 CELLS; HUMANS; KINETICS; MICROSCOPY, FLUORESCENCE; MUTATION; NAPHTHYRIDINES; NUCLEAR RECEPTOR COACTIVATOR 1; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SPIRONOLACTONE; TRANSCRIPTIONAL ACTIVATION;

EID: 84941337023     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.657957     Document Type: Article

References (57)

1. Viengchareun, S., Le Menuet, D., Martinerie, L., Munier, M., Pascual-Le Tallec, L., and Lombès, M. (2007) The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl. Recept. Signal. 5, e012.
2. Funder, J. W. (2010) Aldosterone and mineralocorticoid receptors: Past, present, and future. Endocrinology 151, 5098-5102.
3. Tomaschitz, A., Pilz, S., Ritz, E., Obermayer-Pietsch, B., and Pieber, T. R. (2010) Aldosterone and arterial hypertension. Nat. Rev. Endocrinol. 6, 83-93.
4. Rossi, G. P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.-J., Montemurro, D., Palumbo, G., Rizzoni, D., Rossi, E., Pessina, A. C., Mantero, F., and PAPY Study Participants (2006) Renal damage in primary aldosteronism: Results of the PAPY Study. Hypertension 48, 232-238.
5. Epstein, M. (2006) Aldosterone blockade: An emerging strategy for abrogating progressive renal disease. Am. J. Med. 119, 912-919.
6. Corvol, P., Claire, M., Rafestin-Oblin, M. E., Michaud, A., Roth-Meyer, C., and Menard, J. (1977) Spirolactones: clinical and pharmacologic studies. Adv. Nephrol. Necker Hosp. 7, 199-215.
7. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717.
8. Corvol, P., Michaud, A., Menard, J., Freifeld, M., and Mahoudeau, J. (1975) Antiandrogenic effect of spirolactones: Mechanism of action. Endocrinology 97, 52-58.
9. Schane, H. P., and Potts, G. O. (1978) Oral progestational activity of spironolactone. J. Clin. Endocrinol. Metab. 47, 691-694.
10. Brass, E. P. (1984) Effects of antihypertensive drugs on endocrine function Drugs 27, 447-458.
11. Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., and Redelmeier, D. A. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543-551.
12. Kolkhof, P., and Borden, S. A. (2012) Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol. Cell Endocrinol. 350, 310-317.
13. Bärfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa-Pérez, S., Heckroth, H., Nitsche, A., Ergüden, J.-K., Gielen-Haertwig, H., Schlemmer, K.-H., Mittendorf, J., Paulsen, H., Platzek, J., and Kolkhof, P. (2012) Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. Chem Med Chem. 7, 1385-1403.
14. Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Bärfacker, L., Eitner, F., Albrecht-Küpper, B., and Schäfer, S. (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64, 69-78.
15. Pascual-Le Tallec, L., and Lombès, M. (2005) The mineralocorticoid receptor: A journey exploring its diversity and specificity of action. Mol. Endocrinol. 19, 2211-2221.
16. Lombès, M., Binart, N., Delahaye, F., Baulieu, E. E., and Rafestin-Oblin, M. E. (1994) Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. Biochem. J. 302, 191-197.
17. Grossmann, C., Ruhs, S., Langenbruch, L., Mildenberger, S., Strätz, N., Schumann, K., and Gekle, M. (2012) Nuclear shuttling precedes dimerization in mineralocorticoid receptor signaling. Chem. Biol. 19, 742-751.
18. Tallec, L. P., Kirsh, O., Lecomte, M. C., Viengchareun, S., Zennaro, M. C., Dejean, A., and Lombès, M. (2003) Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol. Endocrinol. 17, 2529-2542.
19. Coustal, S., Fagart, J., Davioud, E., and Marquet, A. (1995) Synthesis of potential cytochrome P45011-gererated intermediates. Tetrahedron 51, 3559-3570.
20. Auzou, G., Fagart, J., Souque, A., Hellal-Lévy, C., Wurtz, J. M., Moras, D., and Rafestin-Oblin, M. E. (2000) A single amino acid mutation of Ala-773 in the mineralocorticoid receptor confers agonist properties to 11-substituted spirolactones. Mol. Pharmacol. 58, 684-691.
21. Fagart, J., Huyet, J., Pinon, G. M., Rochel, M., Mayer, C., and Rafestin- Oblin, M. E. (2005) Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat. Struct. Mol. Biol. 12, 554-555.
22. Fagart, J., Wurtz, J. M., Souque, A., Hellal-Levy, C., Moras, D., and Rafestin- Oblin, M. E. (1998) Antagonism in the human mineralocorticoid receptor. EMBO J. 17, 3317-3325.
23. Fagart, J., Seguin, C., Pinon, G. M., and Rafestin-Oblin, M. E. (2005) The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor. Mol. Pharmacol. 67, 1714-1722.
24. Huyet, J., Pinon, G. M., Fay, M. R., Fagart, J., and Rafestin-Oblin, M. E. (2007) Structural basis of spirolactone recognition by the mineralocorticoid receptor. Mol. Pharmacol. 72, 563-571.
25. Gouilleux, F., Sola, B., Couette, B., and Richard-Foy, H. (1991) Cooperation between structural elements in hormono-regulated transcription from the mouse mammary tumor virus promoter. Nucleic Acids Res. 19, 1563-1569.
26. Deppe, C. E., Heering, P. J., Viengchareun, S., Grabensee, B., Farman, N., and Lombès, M. (2002) Cyclosporine a and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: A cell-based model to investigate partial aldosterone resistance in kidney transplantation. Endocrinology 143, 1932-1941.
27. Viengchareun, S., Kamenicky, P., Teixeira, M., Butlen, D., Meduri, G., Blanchard-Gutton, N., Kurschat, C., Lanel, A., Martinerie, L., Sztal-Mazer, S., Blot-Chabaud, M., Ferrary, E., Cherradi, N., and Lombès, M. (2009) Osmotic stress regulates mineralocorticoid receptor expression in a novel aldosterone-sensitive cortical collecting duct cell line. Mol. Endocrinol. 23, 1948-1962.
28. Williams, R. G., Kandasamy, R., Nickischer, D., Trask, O. J. Jr., Laethem, C., Johnston, P. A., and Johnston, P. A. (2006) Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogen-activated protein kinase inhibitors. Methods Enzymol. 414, 364-389.
29. Fagart, J., Hillisch, A., Huyet, J., Bärfacker, L., Fay, M., Pleiss, U., Pook, E., Schäfer, S., Rafestin-Oblin, M. E., and Kolkhof, P. (2010) A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J. Biol. Chem. 285, 29932-29940.
30. Claire, M., Rafestin-Oblin, M. E., Michaud, A., Corvol, P., Venot, A., Roth- Meyer, C., Boisvieux, J. F., and Mallet, A. (1978) Statistical test of models and computerised parameter estimation for aldosterone binding in rat kidney. FEBS Lett. 88, 295-299.
31. Li, Y., Suino, K., Daugherty, J., and Xu, H. E. (2005) Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol. Cell 19, 367-380.
32. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: A new approach for rapid, accurate docking and scoring: 1. method and assessment of docking accuracy. J. Med. Chem. 47, 1739-1749.
33. Jorgensen, W. L., Maxwell, D. S., and Tirado-Rives, J. (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118, 11225-11236.
34. Khan, J. A., Tikad, A., Fay, M., Hamze, A., Fagart, J., Chabbert-Buffet, N., Meduri, G., Amazit, L., Brion, J. D., Alami, M., Lombès, M., Loosfelt, H., and Rafestin-Oblin, M. E. (2013) A new strategy for selective targeting of progesterone receptor with passive antagonists. Mol. Endocrinol. 27, 909-924.
35. Shen, T., Horwitz, K. B., and Lange, C. A. (2001) Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell Biol. 21, 6122-6131.
36. Lonard, D. M., Nawaz, Z., Smith, C. L., and O'Malley, B. W. (2000) The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell 5, 939-948.
37. Amazit, L., Roseau, A., Khan, J. A., Chauchereau, A., Tyagi, R. K., Loosfelt, H., Leclerc, P., Lombès, M., and Guiochon-Mantel, A. (2011) Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity. Mol. Endocrinol. 25, 394-408.
38. Le Billan, F., Khan, J. A., Lamribet, K., Viengchareun, S., Bouligand, J., Fagart, J., and Lombes, M. (2015) Cistrome of the aldosterone-activated mineralocorticoid receptor in human renal cells. FASEB J. 10.1096/fj.15-274266.
39. Robert-Nicoud, M., Flahaut, M., Elalouf, J. M., Nicod, M., Salinas, M., Bens, M., Doucet, A., Wincker, P., Artiguenave, F., Horisberger, J. D., Vandewalle, A., Rossier, B. C., and Firsov, D. (2001) Transcriptome of a mouse kidney cortical collecting duct cell line: Effects of aldosterone and vasopressin. Proc. Natl. Acad. Sci. U.S.A. 98, 2712-2716.
40. Geller, D. S., Farhi, A., Pinkerton, N., Fradley, M., Moritz, M., Spitzer, A., Meinke, G., Tsai, F. T., Sigler, P. B., and Lifton, R. P. (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289, 119-123.
41. Bledsoe, R. K., Madauss, K. P., Holt, J. A., Apolito, C. J., Lambert, M. H., Pearce, K. H., Stanley, T. B., Stewart, E. L., Trump, R. P., Willson, T. M., and Williams, S. P. (2005) A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J. Biol. Chem. 280, 31283-31293.
42. Zhang, J., and Geller, D. S. (2008) Helix 3-helix 5 interactions in steroid hormone receptor function. J. Steroid Biochem. Mol. Biol. 109, 279-285.
43. Rossier, B. C., Claire, M., Rafestin-Oblin, M. E., Geering, K., Gäggeler, H. P., and Corvol, P. (1983) Binding and antimineralocorticoid activities of spirolactones in toad bladder. Am. J. Physiol. 244, C24-C31.
44. Casals-Stenzel, J., Buse, M., Wambach, G., and Losert, W. (1984) The renal action of spirorenone and other 6β, 7β; 15β, 16β-dimethylene-17- spirolactones, a new type of steroidal aldosterone antagonists. Arzneimit- Telforschung 34, 241-246.
45. Chinn, L. J., Salamon, K. W., and Desai, B. N. (1981) A structure-activity relationship study of spirolactones: contribution of the cyclopropane ring to antimineralocorticoid activity. J. Med. Chem. 24, 1103-1107.
46. de Gasparo, M., Joss, U., Ramjoué, H. P., Whitebread, S. E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., and Schmidlin, J. (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650-656.
47. Gekle, M., Bretschneider, M., Meinel, S., Ruhs, S., and Grossmann, C. (2014) Rapid mineralocorticoid receptor trafficking. Steroids 81, 103-108.
48. Fejes-Tóth, G., Pearce, D., and Náray-Fejes-Tóth, A. (1998) Subcellular localization of mineralocorticoid receptors in living cells: Effects of receptor agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 95, 2973-2978.
49. Tyagi, R. K., Lavrovsky, Y., Ahn, S. C., Song, C. S., Chatterjee, B., and Roy, A. K. (2000) Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol. 14, 1162-1174.
50. Dauvois, S., White, R., and Parker, M. G. (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106, 1377-1388.
51. Devin-Leclerc, J., Meng, X., Delahaye, F., Leclerc, P., Baulieu, E. E., and Catelli, M. G. (1998) Interaction and dissociation by ligands of estrogen receptor and Hsp90: The antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm. Mol. Endocrinol. 12, 842-854.
52. Faresse, N., Vitagliano, J.-J., and Staub, O. (2012) Differential ubiquitylation of the mineralocorticoid receptor is regulated by phosphorylation. FASEB J. 26, 4373-4382.
53. Yokota, K., Shibata, H., Kobayashi, S., Suda, N., Murai, A., Kurihara, I., Saito, I., and Saruta, T. (2004) Proteasome-mediated mineralocorticoid receptor degradation attenuates transcriptional response to aldosterone. Endocr. Res. 30, 611-616.
54. Tirard, M., Almeida, O. F., Hutzler, P., Melchior, F., and Michaelidis, T. M. (2007) Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor. Mol. Cell Endocrinol. 268, 20-29.
55. Liu, Z., Auboeuf, D., Wong, J., Chen, J. D., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (2002) Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. U.S.A. 99, 7940-7944.
56. Cargnelli, G., Trevisi, L., Debetto, P., Luciani, S., and Bova, S. (2001) Effects of canrenone on aorta and right ventricle of the rat. J. Cardiovasc. Pharmacol. 37, 540-547.
57. Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H., Nowack, C., Kolkhof, P., Kim, S.-Y., and Zannad, F. (2013) Safety and tolerability of the novel nonsteroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur. Heart J. 34, 2453-2463.